Tibet Weixinkang Medicine Past Earnings Performance
Past criteria checks 3/6
Tibet Weixinkang Medicine has been growing earnings at an average annual rate of 36.1%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 16.6% per year. Tibet Weixinkang Medicine's return on equity is 17.3%, and it has net margins of 19.3%.
Key information
36.1%
Earnings growth rate
35.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 16.6% |
| Return on equity | 17.3% |
| Net Margin | 19.3% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Tibet Weixinkang Medicine makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,290 | 249 | 391 | 122 |
| 31 Dec 23 | 1,323 | 214 | 402 | 113 |
| 30 Sep 23 | 1,393 | 236 | 433 | 102 |
| 30 Jun 23 | 1,480 | 208 | 477 | 90 |
| 31 Mar 23 | 1,434 | 198 | 470 | 78 |
| 31 Dec 22 | 1,399 | 177 | 484 | 72 |
| 30 Sep 22 | 1,349 | 165 | 461 | 57 |
| 30 Jun 22 | 1,202 | 146 | 427 | 49 |
| 31 Mar 22 | 1,141 | 116 | 418 | 44 |
| 31 Dec 21 | 1,034 | 96 | 388 | 38 |
| 30 Sep 21 | 1,001 | 96 | 354 | 33 |
| 30 Jun 21 | 934 | 82 | 328 | 27 |
| 31 Mar 21 | 794 | 66 | 294 | 22 |
| 31 Dec 20 | 716 | 58 | 263 | 21 |
| 30 Sep 20 | 659 | 56 | 253 | 14 |
| 30 Jun 20 | 675 | 48 | 258 | 20 |
| 31 Mar 20 | 716 | 46 | 263 | 23 |
| 31 Dec 19 | 741 | 56 | 275 | 26 |
| 30 Sep 19 | 817 | 53 | 303 | 26 |
| 30 Jun 19 | 793 | 54 | 312 | 25 |
| 31 Mar 19 | 747 | 60 | 287 | 24 |
| 31 Dec 18 | 746 | 73 | 270 | 21 |
| 30 Sep 18 | 616 | 89 | 226 | 21 |
| 30 Jun 18 | 532 | 93 | 153 | 31 |
| 31 Mar 18 | 497 | 115 | 157 | 27 |
| 31 Dec 17 | 420 | 102 | 138 | 23 |
| 30 Sep 17 | 421 | 113 | 122 | 18 |
| 30 Jun 17 | 402 | 115 | 144 | 0 |
| 31 Mar 17 | 425 | 114 | 173 | 0 |
| 31 Dec 16 | 426 | 115 | 148 | 0 |
| 31 Dec 15 | 440 | 113 | 153 | 0 |
| 31 Dec 14 | 391 | 107 | 135 | 0 |
Quality Earnings: 603676 has a large one-off gain of CN¥53.3M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: 603676's current net profit margins (19.3%) are higher than last year (13.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603676's earnings have grown significantly by 36.1% per year over the past 5 years.
Accelerating Growth: 603676's earnings growth over the past year (25.4%) is below its 5-year average (36.1% per year).
Earnings vs Industry: 603676 earnings growth over the past year (25.4%) exceeded the Pharmaceuticals industry -0.5%.
Return on Equity
High ROE: 603676's Return on Equity (17.3%) is considered low.